ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
8 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
3 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
4 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
4 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
0 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
1 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
3 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
6 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
13 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
10 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
4 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
6 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
13 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
3 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
2 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
3 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
13 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
ODAC Session Live Chat
|
|
lindym
|
50 |
16K |
0 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
50
|
16K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
7 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
2 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
lindym
|
2.0K |
695K |
0 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
695K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
ODAC Session Live Chat
|
|
lindym
|
50 |
16K |
2 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
50
|
16K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
FDA ODAC Meeting Material discussion analysis
|
|
lindym
|
491 |
193K |
1 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
491
|
193K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
lindym
|
854 |
432K |
39 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
854
|
432K
|
39
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
lindym
|
17K |
6.8M |
10 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
17K
|
6.8M
|
10
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
41 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
23K
|
13M
|
41
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
13 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
23K
|
13M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
lindym
|
854 |
432K |
14 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
854
|
432K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
lindym
|
854 |
432K |
29 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
432K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
MSB podcast (10 minutes)
|
|
lindym
|
4 |
2.7K |
6 |
25/07/20 |
25/07/20 |
ASX - By Stock
|
4
|
2.7K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
lindym
|
17K |
6.8M |
33 |
25/07/20 |
25/07/20 |
ASX - By Stock
|
17K
|
6.8M
|
33
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
lindym
|
17K |
6.8M |
18 |
24/07/20 |
24/07/20 |
ASX - By Stock
|
17K
|
6.8M
|
18
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
2 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
8 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
6 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
23K
|
13M
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
18 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
23K
|
13M
|
18
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
2 |
20/07/20 |
20/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Investors in MSB / MESO competitors research us
|
|
lindym
|
48 |
28K |
21 |
18/07/20 |
18/07/20 |
ASX - By Stock
|
48
|
28K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Dr. Michael Bowdish - Reflections on MSB's NIH Trial
|
|
lindym
|
185 |
60K |
25 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
185
|
60K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Dr. Michael Bowdish - Reflections on MSB's NIH Trial
|
|
lindym
|
185 |
60K |
15 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
185
|
60K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Dr. Michael Bowdish - Reflections on MSB's NIH Trial
|
|
lindym
|
185 |
60K |
7 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
185
|
60K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Dr. Michael Bowdish - Reflections on MSB's NIH Trial
|
|
lindym
|
185 |
60K |
37 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
185
|
60K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Multisystem Inflammatory Syndrome in Children (MIS-C)
|
|
lindym
|
164 |
62K |
15 |
03/07/20 |
03/07/20 |
ASX - By Stock
|
164
|
62K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Multisystem Inflammatory Syndrome in Children (MIS-C)
|
|
lindym
|
164 |
62K |
21 |
03/07/20 |
03/07/20 |
ASX - By Stock
|
164
|
62K
|
21
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
lindym
|
23K |
13M |
7 |
27/06/20 |
27/06/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
lindym
|
1.0K |
494K |
9 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
1.0K
|
494K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
clinicaltrials.gov - MSCs in COVID-19 ARDS
|
|
lindym
|
199 |
94K |
20 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
199
|
94K
|
20
|
|